SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss

Journal of Bone and Mineral Research

Volumn 29, Issue 12, 2014, Pages 2618-2635

  Mukai, Tomoyuki ^a   Ishida, Shu ^a,b   Ishikawa, Remi ^a,c   Yoshitaka, Teruhito ^a   Kittaka, Mizuho ^a,b   Gallant, Richard ^a   Lin, Yi Ling ^d   Rottapel, Robert ^e,f   Brotto, Marco ^g   Reichenberger, Ernst J ^h   Ueki, Yasuyoshi ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF DENTISTRY   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d UCLA SCHOOL OF DENTISTRY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Arthritis; Cherubism; Osteoclast; SH3BP2; TNF

Indexed keywords

ADAPTOR PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE SYK; SH3BP2 PROTEIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NFATC1 PROTEIN, MOUSE; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE KINASE; SH3BP2 PROTEIN, MOUSE; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; CYTOKINE PRODUCTION; FIBROUS DYSPLASIA; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MORPHOMETRICS; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; ANIMAL; GENETICS; METABOLISM; MUTATION; OSTEOLYSIS; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE RESORPTION; CHERUBISM; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MUTATION; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHOLIPASE C GAMMA; PROTEIN-TYROSINE KINASES; RANK LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910617399     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2295     Document Type: Article

References (70)

1. Southgate J, Sarma U, Townend JV, Barron J, Flanagan AM. Study of the cell biology and biochemistry of cherubism. J Clin Pathol. 1998;51(11): 831-7.
2. Tiziani V, Reichenberger E, Buzzo CL, et al. The gene for cherubism maps to chromosome 4p16. Am J Hum Genet. 1999;65(1): 158-66.
3. Ueki Y, Tiziani V, Santanna C, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001; 28(2): 125-6.
4. Ren R, Mayer BJ, Cicchetti P, Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science. 1993;259(5098): 1157-61.
5. Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A. Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity. 1998;9(5): 595-605.
6. Foucault I, Liu YC, Bernard A, Deckert M. The chaperone protein 14-3- 3 in teracts with 3BP2/SH3BP2 and regulates its adapter function. J Biol Chem. 2003;278(9): 7146-53.
7. Foucault I, Le Bras S, Charvet C, Moon C, Altman A, Deckert M. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood. 2005;105(3): 1106-13.
8. Maeno K, Sada K, Kyo S, et al. Adaptor protein 3BP2 is a potential ligand of Src homology 2 and 3 domains of Lyn protein-tyrosine kinase. J Biol Chem. 2003;278(27): 24912-20.
9. Jevremovic D, Billadeau DD, Schoon RA, Dick CJ, Leibson PJ. Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2. J Immunol. 2001;166(12): 7219-28.
10. Yu Z, Maoui M, Zhao ZJ, Li Y, Shen SH. SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. FEBS J. 2006;273(10): 2195-205.
11. Chihara K, Nakashima K, Takeuchi K, Sada K. Association of 3BP2 with SHP-1 regulates SHP-1-mediated production of TNF-αlpha in RBL- 2H3 cells. Genes Cells. 2011;16(12): 1133-45.
12. Shukla U, Hatani T, Nakashima K, Ogi K, Sada K. Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT. J Biol Chem. 2009;284(49): 33719-28.
13. Levaot N, Simoncic PD, Dimitriou ID, et al. 3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions. J Clin Invest. 2011;121(8): 3244-57.
14. Chen G, Dimitriou ID, La Rose J, et al. The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol. 2007;27(8): 3109-22.
15. de la Fuente MA, Kumar L, Lu B, Geha RS. 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. Mol Cell Biol. 2006;26(14): 5214-25.
16. Ueki Y, Lin CY, Senoo M, et al. Increased myeloid cell responses to MCSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell. 2007;128(1): 71-83.
17. Levaot N, Voytyuk O, Dimitriou I, et al. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell. 2011;147(6): 1324-39.
18. Guettler S, LaRose J, Petsalaki E, et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell. 2011;147(6): 1340-54.
19. Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7(4): 292-304.
20. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002;30(2): 340-6.
21. Nanes MS. Tumor necrosis factor-alpha: Molecular and cellular mechanisms in skeletal pathology. Gene. 2003;321: 1-15.
22. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol. 2009;201(3): 309-20.
23. Redlich K, Smolen JS. Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11(3): 234-50.
24. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-αlpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12): 1481-8.
25. Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest. 2009;119(10): 3024-34.
26. Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med. 2012;209(2): 319-34.
27. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000;191(2): 275-86.
28. KimN, Kadono Y, TakamiM, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005;202(5): 589-95.
29. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNFinduced osteoclastogenesis. J Clin Invest. 2005;115(2): 282-90.
30. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, regulation of bone mass, calcium metabolism. Proc Natl Acad Sci U S.A. 2000;97(4): 1566-71.
31. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002;143(3): 1108-18.
32. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factoralpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000;275(7): 4858-64.
33. Hero M, Suomalainen A, Hagstrom J, et al. Anti-tumor necrosis factor treatment in cherubism-clinical, radiological and histological findings in two children. Bone. 2013;52(1): 347-53.
34. Aliprantis AO, Ueki Y, Sulyanto R, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 2008; 118(11): 3775-89.
35. Hayward MD, Jones BK, Saparov A, et al. An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol. 2007;7: 13.
36. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Naphthol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J Bone Miner Res. 2001;16(4): 788-93.
37. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10(6): 617-24.
38. Tanabe N, Wheal BD, Kwon J, et al. Osteopontin signals through calcium and nuclear factor of activated T cells (NFAT) in osteoclasts: A novel RGD-dependent pathway promoting cell survival. J Biol Chem. 2011;286(46): 39871-81.
39. Kitamura T. New experimental approaches in retrovirus-mediated expression screening. Int J Hematol. 1998;67(4): 351-9.
40. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest. 2005;115(12): 3418-27.
41. Proulx ST, Kwok E, You Z, et al. Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum. 2007;56(12): 4024-37.
42. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25(7): 1468-86.
43. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28(1): 2-17.
44. Nicholson GC, Malakellis M, Collier FM, et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond). 2000;99(2): 133-40.
45. Sorensen MG, Henriksen K, Schaller S, et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab. 2007;25(1): 36-45.
46. Chomette G, Auriol M, Guilbert F, Vaillant JM. Cherubism. Histoenzymological and ultrastructural study. Int J Oral Maxillofac Surg. 1988;17(4): 219-23.
47. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6): 889-901.
48. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9): 1261-9.
49. Zhao B, Takami M, Yamada A, et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med. 2009;15(9): 1066-71.
50. Kim K, Kim JH, Lee J, et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood. 2007;109(8): 3253-9.
51. Miyauchi Y, Ninomiya K, Miyamoto H, et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med. 2010;207(4): 751-62.
52. Nishikawa K, Nakashima T, Hayashi M, et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci U S.A. 2010;107(7): 3117-22.
53. Yarilina A, Xu K, Chen J, Ivashkiv LB. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc Natl Acad Sci U S A. 2011;108(4): 1573-8.
54. Chihara K, Kimura Y, Honjoh C, Yamauchi S, Takeuchi K, Sada K. Tyrosine phosphorylation of 3BP2 is indispensable for the interaction with VAV3 in chicken DT40 cells. Exp Cell Res. 2014;322(1): 99-107.
55. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol. 2010; 10(6): 387-402.
56. GuezGuez A, Prod'homme V, Mouska X, et al. 3BP2 adapter protein is required for receptor activator of NFkappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem. 2010; 285(27): 20952-63.
57. Liu B, Yu SF, Li TJ. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J Oral Pathol Med. 2003;32(6): 367-75.
58. Lee JY, Jung YS, Kim SA, Lee SH, Ahn SG, Yoon JH. Investigation of the SH3BP2 gene mutation in cherubism. Acta Med Okayama. 2008; 62(3): 209-12.
59. Yoshitaka T, Ishida S, Mukai T, Kittaka M, Reichenberger E, Ueki Y. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss. J Bone Miner Res. 2014;29(5): 1170-82.
60. Yamashita T, Yao Z, Li F, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c- Fos and NFATc1. J Biol Chem. 2007;282(25): 18245-53.
61. Lee SE, Chung WJ, Kwak HB, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem. 2001;276(52): 49343-9.
62. Mocsai A, Humphrey MB, Van Ziffle JA, et al. The immunomodulatory adapter proteins DAP12, Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S.A. 2004;101(16): 6158-63.
63. Faccio R, Zou W, Colaianni G, Teitelbaum SL, Ross FP. High dose MCSF partially rescues the Dap12-/- osteoclast phenotype. J Cell Biochem. 2003;90(5): 871-83.
64. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest. 2006;116(11): 2869-79.
65. Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis. J Immunol. 2004;173(2): 1066-77.
66. Ainsua-Enrich E, Alvarez-Errico D, Gilfillan AM, et al. The adaptor 3BP2 is required for early and late events in FcepsilonRI signaling in human mast cells. J Immunol. 2012;189(6): 2727-34.
67. Negishi-Koga T, Takayanagi H. Ca2+ -NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231(1): 241-56.
68. Lietman SA, Prescott NL, Hicks DG, Westra WH, Levine MA. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism. Clin Orthop Relat Res. 2007;459: 22-7.
69. Watanabe D, Hashimoto S, Ishiai M, et al. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptorcoupled calcium signaling. J Biol Chem. 2001;276(42): 38595-601.
70. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001;276(1): 563-8.